ALNY vs SLN: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
ALNY is the larger of the two ($20.29B market cap): the incumbent the market prices for continued execution (13.98x forward earnings, beta 0.44). SLN is the smaller challenger ($1.23B), priced similarly on forward earnings (-51.99x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ALNY vs SLN: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ALNY | SLN | What it tells you |
|---|---|---|---|
| Market cap | $20.29B | $1.23B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 13.98 | -51.99 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.44 | 1.34 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 0% of range | 99% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.63 | 24.27 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ALNY and SLN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALNY and SLN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALNY and SLN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Alnylam Pharmaceuticals (ALNY) do?
Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines. Its commercial portfolio includes Amvuttra (vutrisiran) and Onpattro for transthyretin (TTR) amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for a rare kidney disorder, plus royalties on Leqvio, an cholesterol-lowering RNAi drug marketed by partner Novartis. The defining event was the March 2025 FDA approval of Amvuttra for ATTR amyloidosis with cardiomyopathy (ATTR-CM), a far larger patient population than its earlier polyneuropathy indication, based on the HELIOS-B trial showing a 28% reduction in death and cardiac events.
What does Silence Therapeutics (SLN) do?
Silence Therapeutics plc is a London-headquartered biotechnology company built around short interfering RNA, a class of drug that switches off the production of a specific disease-causing protein in the liver rather than blocking it after the fact. Its proprietary discovery platform, marketed as mRNAi GOLD, attaches a GalNAc sugar to the siRNA so the molecule is taken up by liver cells, which is the same delivery approach behind the approved RNAi drugs on the market today. Two candidates carry the story. Zerlasiran silences the LPA gene to lower lipoprotein(a), an inherited cardiovascular risk factor with no approved therapy, and produced reductions of more than 80 percent in its Phase 2 ALPACAR-360 trial. Divesiran targets TMPRSS6 to raise hepcidin and control red blood cell production in polycythemia vera, a chronic blood cancer whose patients are otherwise managed with repeated therapeutic phlebotomy. A third asset, SLN312, was returned to Silence in March 2026 after AstraZeneca elected not to advance it past Phase 1.
ALNY vs SLN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ALNY drivers: Amvuttra ATTR-CM ramp; Crossing into sustained profitability.
- SLN drivers: Divesiran after a positive SANRECO Phase 2; A partner for zerlasiran.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Revenue is heavily concentrated in the TTR franchise, and the July 2026 guidance cut showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the total revenue range produced a 28% one-day drop. For SLN, silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings.
ALNY or SLN: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALNY if you believe its drivers more; SLN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALNY and SLN guides.
ALNY vs SLN: the full fundamentals
ALNY. After a 41% decline in 2026, Alnylam trades at about 6.6 times trailing revenue, near 40 times trailing earnings and about 19 times forward earnings, a much lower multiple than when guidance was first set. Consensus still expects about $5.5 billion of total revenue in 2026 and about $6.9 billion in 2027, so the valuation now hinges on whether the Q3 report on October 29 shows Amvuttra growth steadying after the guidance cut. It pays no dividend and reinvests cash into its RNAi pipeline.
SLN. Conventional valuation multiples do not apply: trailing revenue is under $1 million, so price-to-sales (about 890x) and price-to-earnings are arithmetic noise. Adding the roughly $201 million of gross offering proceeds to the $72 million held at June 30 suggests cash in the region of $250 million or more after fees and third-quarter spending, so a roughly $548 million market cap implies the market values divesiran, zerlasiran and the platform at about $300 million. Figures are approximate and as of October 16, 2026; the third-quarter report, expected around November 5 (an estimated date), will show the actual post-raise cash balance.
Headline figures (approximate, October 2026): ALNY shows total revenue (ttm) ~$4.8B, net product revenue growth (q2 2026 yoy) ~74% (to ~$1.17B), amvuttra revenue (q2 2026) ~$1.01B, up ~106%, 2026 net product revenue guidance ~$4.7B to $5.1B (cut from $4.9B to $5.3B); SLN shows market cap ~$548M (at ~$8.81 per ADS, Oct 16, 2026), revenue (ttm) ~$0.6M (collaboration revenue only, down from ~$34M in FY2024), net loss (ttm) ~$60M; Q2 2026 net loss ~$9M, eps per ads (trailing / forward) ~-$1.29 / ~-$0.38.
The bottom line: ALNY vs SLN
ALNY and SLN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALNY and SLN exposure against your real portfolio. It is not an investment adviser.
Wondering how ALNY or SLN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Alnylam Pharmaceuticals
Ask Walnut's AI anything about ALNY and see how it fits what you own.
FAQ
What is the difference between ALNY and SLN?
+
Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines. Silence Therapeutics plc is a London-headquartered biotechnology company built around short interfering RNA, a class of drug that switches off the production of a specific disease-causing protein in the liver rather than blocking it after the fact. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ALNY or SLN the better stock?
+
Neither is universally better. ALNY is the larger incumbent; SLN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ALNY or SLN?
+
On forward P/E (as of November 2026), ALNY trades at 13.98x and SLN at -51.99x, so SLN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ALNY and SLN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ALNY vs SLN?
+
ALNY: Revenue is heavily concentrated in the TTR franchise, and the July 2026 guidance cut showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the total revenue range produced a 28% one-day drop. The ATTR-CM market is a genuine contest, with Pfizer's entrenched tafamidis (Vyndaqel/Vyndamax), BridgeBio's oral acoramidis (Attruby), and Ionis/AstraZeneca's eplontersen (Wainua) all competing, and new RNAi entrants keep raising capital. Biotech valuations are sensitive to clinical trial outcomes, and pipeline readouts in Alzheimer's and other areas could disappoint. Even after the slide, the stock trades near 40 times trailing earnings, which assumes years of strong growth. Drug pricing pressure, including government price negotiation under the Inflation Reduction Act, and patent or regulatory changes are ongoing overhangs. Debt of about $3.0 billion sits roughly level with the cash balance. SLN: Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. The SANRECO Phase 2 succeeded, but Phase 2 results in 48 patients do not guarantee a Phase 3 win, and the planned Phase 3 will take years and consume a large part of the cash raised in August 2026. A partner for zerlasiran may not appear on acceptable economics or at all, which would leave the larger asset stranded. Dilution is no longer hypothetical: the August offering added about 14.9 million ADSs at $13.50, and the stock has since traded well below that price, closing near $8.81 on October 16, 2026 after a 28% fall in a month. Competition is well funded on both fronts: several large pharmaceutical companies are running Phase 3 lipoprotein(a) programs, and polycythemia vera already has approved and late-stage alternatives, including rusfertide aimed at the same hepcidin biology. Because the ADSs represent three ordinary shares each, per-share figures quoted for the Nasdaq listing and the underlying UK share count are not directly comparable, which is a frequent source of confusion when reading coverage.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALNY or SLN; figures are approximate and dated (as of November 2026). Verify current data before investing.